- Home
- DCTH vs JGH Comparison
DCTH vs JGH Comparison
Compare DCTH & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- JGH
- Stock Information
- Founded
- DCTH 1988
- JGH 2014
- Country
- DCTH United States
- JGH United States
- Employees
- DCTH N/A
- JGH N/A
- Industry
- DCTH Medical/Dental Instruments
- JGH Investment Managers
- Sector
- DCTH Health Care
- JGH Finance
- Exchange
- DCTH Nasdaq
- JGH Nasdaq
- Market Cap
- DCTH 352.0M
- JGH 308.3M
- IPO Year
- DCTH N/A
- JGH N/A
- Fundamental
- Price
- DCTH $11.34
- JGH $12.76
- Analyst Decision
- DCTH Strong Buy
- JGH
- Analyst Count
- DCTH 4
- JGH 0
- Target Price
- DCTH $21.50
- JGH N/A
- AVG Volume (30 Days)
- DCTH 346.0K
- JGH 73.9K
- Earning Date
- DCTH 11-08-2024
- JGH 01-01-0001
- Dividend Yield
- DCTH N/A
- JGH 9.85%
- EPS Growth
- DCTH N/A
- JGH N/A
- EPS
- DCTH N/A
- JGH N/A
- Revenue
- DCTH $22,644,000.00
- JGH N/A
- Revenue This Year
- DCTH $1,605.13
- JGH N/A
- Revenue Next Year
- DCTH $111.67
- JGH N/A
- P/E Ratio
- DCTH N/A
- JGH N/A
- Revenue Growth
- DCTH 945.91
- JGH N/A
- 52 Week Low
- DCTH $3.70
- JGH $10.36
- 52 Week High
- DCTH $13.30
- JGH $12.85
- Technical
- Relative Strength Index (RSI)
- DCTH 51.29
- JGH 30.57
- Support Level
- DCTH $10.75
- JGH $12.65
- Resistance Level
- DCTH $13.30
- JGH $13.38
- Average True Range (ATR)
- DCTH 0.70
- JGH 0.12
- MACD
- DCTH -0.12
- JGH -0.07
- Stochastic Oscillator
- DCTH 23.13
- JGH 15.07
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.